{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:20:36Z","timestamp":1791159636472,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NCI 5 SC1 CA138177"],"award-info":[{"award-number":["NCI 5 SC1 CA138177"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.nucmedbio.2013.12.015","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T02:33:09Z","timestamp":1388716389000},"page":"276-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: Comparison with 188Re radiolabel"],"prefix":"10.1016","volume":"41","author":[{"given":"S.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Revskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sisay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.S.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dadachova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.C.","family":"Francesconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0005","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/jid.2008.423","article-title":"Increasing burden of melanoma in the United States","volume":"129","author":"Linos","year":"2009","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0015","article-title":"Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma","volume":"29","author":"Chapman","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0020","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8509","article-title":"BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma","volume":"29","author":"Ribas","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0025","doi-asserted-by":"crossref","first-page":"14865","DOI":"10.1073\/pnas.0406180101","article-title":"Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin","volume":"101","author":"Dadachova","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0030","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.4161\/cbt.7.7.6197","article-title":"Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice","volume":"7","author":"Dadachova","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0035","article-title":"Safety and efficacy of 188-Rhenium-labeled antibody to melanin in patients with metastatic melanoma","volume":"828329","author":"Klein","year":"2013","journal-title":"J. Skin Cancer"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.critrevonc.2008.02.006","article-title":"Peptide-targeted radionuclide therapy for melanoma","volume":"67","author":"Miao","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/bc0502356","article-title":"Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates of 149Pm, 166Ho, 177Lu","volume":"17","author":"Mohsin","year":"2006","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.nucmedbio.2003.08.004","article-title":"Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice","volume":"31","author":"Lewis","year":"2004","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0055","first-page":"761","article-title":"Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro","volume":"18","author":"Capello","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0060","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1021\/bc200258x","article-title":"Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu","volume":"22","author":"Mohsin","year":"2011","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0065","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0969-8051(02)00290-1","article-title":"Pm-149 DOTA bombesin analogs for potential radiotherapy in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-bAla-BBN(7\u201314)NH2","volume":"29","author":"Hu","year":"2002","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0070","series-title":"Guide to protein purification","first-page":"73","article-title":"Quantitation of protein","volume":"463","author":"Noble","year":"2009"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0075","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/bc00016a014","article-title":"Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates","volume":"3","author":"Pippen","year":"1992","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0080","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2967\/jnumed.109.067686","article-title":"Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine","volume":"50","author":"Karacay","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0085","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1158\/1078-0432.CCR-08-0404","article-title":"Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab)","volume":"14","author":"Mattes","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0090","first-page":"436","article-title":"Evaluation of absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 177Lu and 64Cu radioisotopes","volume":"18","author":"Miller","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"issue":"supplement","key":"10.1016\/j.nucmedbio.2013.12.015_bb0095","first-page":"951","article-title":"A mouse model for calculating cross-organ \u03b2 doses from yttrium-90-labeled immunoconjugates","volume":"73","author":"Hui","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0100","first-page":"531","article-title":"Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re-and 99mTc labeled Anti-NCA-95 MAbs","volume":"41","author":"Kotzerke","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0105","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1021\/jm980152t","article-title":"Physical parameters and biological stability of yttrium(III) diethylenetriaminepentaacetic acid derivative conjugates","volume":"41","author":"McMurry","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0110","first-page":"209","article-title":"In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts","volume":"14","author":"Roselli","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0115","first-page":"S568-S568","article-title":"Development of Y-90 Y-CHX-A ''-DTPA-cetuximab for combination of radioimmunotherapy and external radiotherapy: radiochemistry and first in vivo results","volume":"54","author":"Heldt","year":"2011","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0120","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1158\/0008-5472.CAN-03-2382","article-title":"A single treatment of yttrium-90-labeled CHX-A''-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice","volume":"64","author":"Adams","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0125","first-page":"18","article-title":"Yttrium-90 radiolabeled humanized anti-CD25 monoclonal antibody, daclizumab, provides effective therapy for refractory and relapsed Hodgkin's lymphoma","volume":"92","author":"O'Mahony","year":"2007","journal-title":"Haematol Hematol J"},{"issue":"4","key":"10.1016\/j.nucmedbio.2013.12.015_bb0130","first-page":"488","article-title":"Radiotherapy of CD45-expressing daudi tumors in nude mice with yttrium-90-labeled, PEGylated Anti-CD45 antibody","volume":"22","author":"Vallera","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2013.12.015_bb0135","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cmmi.491","article-title":"Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators","volume":"7","author":"D'Huyvetter","year":"2012","journal-title":"Contrast Media Mol Imaging"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805113002631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805113002631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:27:59Z","timestamp":1760848079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805113002631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0969805113002631"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2013.12.015","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: Comparison with 188Re radiolabel","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2013.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}